Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

[1]  R. Schlenk,et al.  Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) , 2016, Leukemia.

[2]  S. Nahas,et al.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.

[3]  G. Mufti,et al.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.

[4]  A. Glasmacher,et al.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.

[5]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[6]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[7]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Woll,et al.  Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.

[9]  L. Saft,et al.  Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression , 2009, Haematologica.

[10]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[11]  M. Gordon.  Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .

[12]  J. Boultwood,et al.  NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). , 2004, Haematologica.

[13]  M. Taniwaki,et al.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.

[14]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[15]  A. Órfão,et al.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. , 1998, Blood.

[16]  Koichi Sugimoto,et al.  Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. , 1993, Blood.